A Phase II Study Assessing the Potential for Reduced Toxicity Using Focal Brachytherapy in Low-Risk Prostate Cancer
[Protocol 11-056] |
Zelefsky, Michael |
|
A Phase IB/IIA Study of Romidepsin plus Lenalidomide in Adults with Relapsed or Refractory Lymphoma and Myeloma
[Protocol 12-170] |
Horwitz, Steven |
|
A Phase IB/IIA Study of ABT-888 in Combination with Bendamustine with or without Rituximab in Patients with Lymphoma, Multiple Myeloma, and Solid Tumors
[Protocol 10-174] |
Gerecitano, John |
|
A Phase IB/II Study of OMP-59R5 with Gemcitabine in Patients with Previously Untreated Metastatic Pancreatic Cancer
[Protocol 12-234] |
O'Reilly, Eileen |
|
A Phase IB/II Study of IPI-504 plus Everolimus in Patients with KRAS-Mutant Non-Small Cell Lung Cancer
[Protocol 11-114] |
Riely, Gregory |
- Lung Cancer
- Lung Cancer, Non-Small Cell
|
A Phase Ib/II Study of Gemcitabine and Docetaxel Plus Pazopanib for the Neoadjuvant (Presurgical) Treatment of Soft-Tissue Sarcoma
[Protocol 11-104] |
Tap, William |
|
A Phase IB/II study of E7080 plus Everolimus in Patients with Unresectable Advanced/Metastatic Renal Cell Carcinoma
[Protocol 10-084] |
Molina, Ana Maria |
|
A Phase IB/II Study Evaluating Doxorubicin with or without a IMC-3G3 to Treat Advanced Soft-Tissue Sarcoma
[Protocol 10-156] |
Tap, William |
|
A Phase IB Study of Vismodegib in Patients with Liver Cancer with Varying Degrees of Kidney and Liver Function
[Protocol 12-031] |
Abou-Alfa, Ghassan |
|
A Phase Ib Study of Trastuzumab-MCC-DM1, Paclitaxel, and Pertuzumab in Patients with HER2-Positive, Locally Advanced or Metastatic Breast Cancer Who Previously Received Trastuzumab
[Protocol 09-093] |
Modi, Shanu |
|
A Phase IB Study of SGN-75 plus Everolimus in Patients with CD70-Positive Metastatic Renal Cell Cancer
[Protocol 12-263] |
Molina, Ana Maria |
|
A Phase IB Study of SAR650984 with Lenalidomide and Dexamethasone to Treat Recurrent or Persistent Multiple Myeloma
[Protocol 13-006] |
Lendvai, Nikoletta |
|
A Phase IB Study of MEK162 plus Paclitaxel in Patients with Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
[Protocol 12-192] |
Grisham, Rachel |
|
A Phase Ib Study of MDX-1106 (BMS-936558) in Combination with Ipilimumab (BMS-734016) in Patients with Unresectable Stage III or Stage IV Malignant Melanoma
[Protocol 09-155] |
Wolchok, Jedd |
|
A Phase Ib Study of Combination Therapy with MSC1936369B and SAR245409 in Patients with Locally Advanced or Metastatic Solid Tumors
[Protocol 12-107] |
Rizvi, Naiyer |
|
A Phase IB Study of BKM120 plus MEK162 in Select Patients with Advanced Solid Tumors
[Protocol 11-117] |
Gounder, Mrinal |
- Breast Cancer
- Colorectal Cancer
- Hepatobiliary
- Lung Cancer
- Lung Cancer, Non-Small Cell
- Upper Gastrointestinal
|
A Phase IB Dose-Escalation and Safety Study of LDE225 plus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Cancer
[Protocol 12-036] |
Yu, Kenneth |
- Hepatobiliary
- Upper Gastrointestinal
|
A Phase IA/B Study of CC-115 in Castration-Resistant Prostate Cancer
[Protocol 12-080] |
Rathkopf, Dana |
- Prostate Cancer
- Metastatic Disease after Hormone-Reducing Therapy
|
A Phase I/IIA Study of Carfilzomib plus High-Dose Melphalan Before Autologous Stem Cell Transplant in Patients with Multiple Myeloma
[Protocol 12-144] |
Landau, Heather |
|
A Phase I/IIa Study of Alpharadin® Plus Docetaxel in Patients with Bone Metastases from Castration-Resistant Prostate Cancer
[Protocol 10-086] |
Morris, Michael |
- Prostate Cancer
- Metastatic Disease after Hormone-Reducing Therapy
|
